DNA‑PKcs phosphorylation specific inhibitor, NU7441, enhances the radiosensitivity of clinically relevant radioresistant oral squamous cell carcinoma cells.
DNA damage response
IBR2
NU7441
radioresistance
Journal
Biomedical reports
ISSN: 2049-9442
Titre abrégé: Biomed Rep
Pays: England
ID NLM: 101613227
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
20
10
2022
accepted:
23
01
2023
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Radioresistant cancer cells lead to poor prognosis after radiotherapy. However, the mechanisms underlying cancer cell radioresistance have not been fully elucidated. Thus, the DNA damage response of clinically relevant radioresistant oral squamous cell carcinoma HSC2-R cells, established by long-term exposure of parental HSC2 cells to fractionated radiation, was investigated. The DNA double-strand break (DSB) repair protein-specific inhibitor, NU7441, which targets DNA-dependent protein kinase catalytic subunit (DNA-PKcs) phosphorylation, and IBR2, which targets Rad51, were administered to HSC2 and HSC2-R cells. NU7441 administration eliminated colony formation in both cell lines under 6 Gy X-ray irradiation, whereas IBR2 did not affect colony formation. NU7441 and IBR2 significantly enhanced 6 Gy X-ray irradiation-induced apoptosis in HSC2-R cells. In HSC2-R cells, cell cycle arrest released earlier than in HSC2 cells, and phosphorylated-H2A histone family member X (γH2AX) expression rapidly decreased. Following NU7441 administration, γH2AX expression and the cell percentages of the G2/M phase were not decreased at 48 h after treatment in HSC2-R cells. DNA-PKcs has been demonstrated to regulate non-homologous end-joining (NHEJ) and homologous recombination (HR) repair, and the later phase of DSB repair is dominated by HR. Therefore, the results of the present study indicated that the DSB repair mechanism in HSC2-R cells strongly depends on NHEJ and loss of HR repair function. The present study revealed a potential mechanism underlying the acquired radioresistance and therapeutic targets in radioresistant cancer cells.
Identifiants
pubmed: 36926187
doi: 10.3892/br.2023.1610
pii: BR-18-4-01610
pmc: PMC10011949
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Informations de copyright
Copyright © 2020, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
EMBO Mol Med. 2013 Mar;5(3):353-65
pubmed: 23341130
Phys Med Biol. 2021 Apr 06;66(7):
pubmed: 33735839
Oncol Lett. 2019 Jun;17(6):5830-5838
pubmed: 31186811
Mutat Res. 2017 Oct;803-805:51-55
pubmed: 28781144
Radiother Oncol. 2013 Sep;108(3):362-9
pubmed: 23849169
Med Mol Morphol. 2017 Dec;50(4):195-204
pubmed: 29067564
Clin Cancer Res. 2017 Jul 15;23(14):3489-3498
pubmed: 28364015
Int J Mol Sci. 2020 Feb 15;21(4):
pubmed: 32075223
Yonago Acta Med. 2017 Mar 09;60(1):9-15
pubmed: 28331416
Clin Oncol (R Coll Radiol). 2014 May;26(5):243-9
pubmed: 24630811
Oncotarget. 2016 Mar 1;7(9):9732-41
pubmed: 26799421
Cancer Sci. 2013 Sep;104(9):1172-7
pubmed: 23714583
Radiother Oncol. 2017 Sep;124(3):455-461
pubmed: 28923575
Cells. 2020 Jul 09;9(7):
pubmed: 32660072
EMBO J. 2011 Mar 16;30(6):1079-92
pubmed: 21317870
Sci Rep. 2022 Jan 20;12(1):1056
pubmed: 35058559
JCI Insight. 2018 Feb 8;3(3):
pubmed: 29415883
Mol Oncol. 2021 Aug;15(8):2219-2234
pubmed: 33523579
Mutat Res. 2013 Aug 30;756(1-2):21-9
pubmed: 23811167
Cell. 2018 Sep 6;174(6):1347-1360
pubmed: 30193109
Radiat Res. 2013 Dec;180(6):584-94
pubmed: 24191898
J Radiat Res. 2019 May 1;60(3):298-307
pubmed: 31034058
Nucleic Acids Res. 2012 Aug;40(14):6585-94
pubmed: 22505579
Sci Rep. 2018 May 29;8(1):8287
pubmed: 29844494
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Cancer Res. 2019 Feb 1;79(3):452-460
pubmed: 30530501
Br J Cancer. 2005 Mar 28;92(6):1089-97
pubmed: 15785736
Cancer Lett. 2021 Nov 1;520:361-373
pubmed: 34389435
Cell Cycle. 2019 Aug;18(15):1770-1783
pubmed: 31238782
Int J Mol Sci. 2018 Oct 03;19(10):
pubmed: 30282933
Nature. 2000 Mar 30;404(6777):510-4
pubmed: 10761921
Trends Cell Biol. 2016 Jan;26(1):52-64
pubmed: 26437586
Front Genet. 2020 Dec 23;11:607428
pubmed: 33424929
Cytometry A. 2004 Apr;58(2):99-110
pubmed: 15057963
Radiat Res. 2009 Mar;171(3):265-73
pubmed: 19267553
Int J Biol Sci. 2020 Jan 1;16(3):408-419
pubmed: 32015678
J Radiat Res. 2010;51(3):297-302
pubmed: 20410675
Mol Cell. 2012 Jul 27;47(2):320-9
pubmed: 22841003
Mol Cancer Ther. 2021 Jul;20(7):1257-1269
pubmed: 33947685
Oncogene. 2010 Aug 26;29(34):4826-37
pubmed: 20562919